8-17-2011

Cyclin-dependent kinase 5 regulates PSD-95 ubiquitination in neurons

Michael J. Bianchetta
University of Massachusetts Medical School, Mike.Bianchetta@umassmed.edu

TuKiet T. Lam
Yale University

Stephen N. Jones
University of Massachusetts Medical School, Stephen.Jones@umassmed.edu

See next page for additional authors

Follow this and additional works at: http://escholarship.umassmed.edu/morabito

Part of the Cell Biology Commons

Repository Citation
Bianchetta, Michael J.; Lam, TuKiet T.; Jones, Stephen N.; and Morabito, Maria A., "Cyclin-dependent kinase 5 regulates PSD-95 ubiquitination in neurons" (2011). Morabito Lab. 7.
http://escholarship.umassmed.edu/morabito/7

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Morabito Lab by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Cyclin-dependent kinase 5 regulates PSD-95 ubiquitination in neurons

Authors
Michael J. Bianchetta, TuKiet T. Lam, Stephen N. Jones, and Maria A. Morabito

Comments
Copyright © 2011 the authors. Copyright of all material published in The Journal of Neuroscience remains with the authors. The authors grant the Society for Neuroscience an exclusive license to publish their work for the first 6 months. After 6 months the work becomes available to the public to copy, distribute, or display under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license.

Rights and Permissions
Citation: J Neurosci. 2011 Aug 17;31(33):12029-35. Link to article on publisher's site

This article is available at eScholarship@UMMS: http://escholarship.umassmed.edu/morabito/7
Cyclin-Dependent Kinase 5 Regulates PSD-95 Ubiquitination in Neurons

Michael J. Bianchetta,1 TuKiet T. Lam,2 Stephen N. Jones,1 and Maria A. Morabito1

1Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01655 and 2W. M. Keck Foundation Biotechnology Resource Laboratory, Yale University, New Haven, Connecticut 06511

Cyclin-dependent kinase 5 (Cdk5) and its activator p35 have been implicated in drug addiction, neurodegenerative diseases such as Alzheimer’s, learning and memory, and synapse maturation and plasticity. However, the molecular mechanisms by which Cdk5 regulates synaptic plasticity are still unclear. PSD-95 is a major postsynaptic scaffolding protein of glutamatergic synapses that regulates synaptic strength and plasticity. PSD-95 is ubiquitinated by the ubiquitin E3 ligase Mdm2, and rapid and transient PSD-95 ubiquitination has been implicated in NMDA receptor-induced AMPA receptor endocytosis. Here we demonstrate that genetic or pharmacological reduction of Cdk5 activity increases the interaction of Mdm2 with PSD-95 and enhances PSD-95 ubiquitination without affecting PSD-95 protein levels in vivo in mice, suggesting a nonproteolytic function of ubiquitinated PSD-95 at synapses. We show that PSD-95 ubiquitination correlates with increased interaction with β-adaptin, a subunit of the clathrin adaptor protein complex AP-2. This interaction is increased by genetic reduction of Cdk5 activity or NMDA receptor stimulation and is dependent on Mdm2. Together these results support a function for Cdk5 in regulating PSD-95 ubiquitination and its interaction with AP-2 and suggest a mechanism by which PSD-95 may regulate NMDA receptor-induced AMPA receptor endocytosis.
either sex were isolated, and 300 μm coronal slices of forebrain (within the region corresponding approximately to −1.0 to −3.5 mm from bregma, containing the hippocampus) were prepared using a Vibratome (VT1000S; Leica Microsystems) in ice-cold oxygenated artificial CSF (ACSF) containing the following (in mM): 117 NaCl, 1.7 KCl, 1.2 MgCl₂, 2.5 CaCl₂, 1.2 NaH₂PO₄, 25 NaHCO₃, and 11.5 glucose. Slices were preincubated in ACSF for 1 h before treatments and all experiments were conducted at 32°C in 95% O₂ and 5% CO₂ incubator. Slice lysates were prepared as described previously (Zhang et al., 2008), and PSD-95 immunoprecipitated from the lysates was analyzed by Western blot and quantified as described above. Values are expressed as mean ± SEM and were statistically compared using Student’s t test or a two-way ANOVA.

Western blots of brain lysates. Brain lysates were prepared according to Zhang et al., (2008). Briefly, brains (without cerebellum) were first homogenized and lysed in 1% deoxycholate (DOC) lysis buffer (150 mM NaCl, 50 mM Tris, pH 8.8, 1% DOC), to which an equal volume of modified RIPA was added (150 mM NaCl, 50 mM Tris/HCl pH 7.4, 1 mM EDTA, 1% Triton X-100, 0.1% SDS) (Kalia et al., 2006). All buffers were supplemented with protease and phosphatase inhibitor cocktails (Roche). Lysate protein concentrations were determined by Detergent Compatible Protein Assay (Bio-Rad). Immunoprecipitations and Western blot analysis were performed as described previously (Zhang et al., 2008). Antibodies used were mouse monoclonals Mdm2 (Millipore), PSD-95 (Antibodies Incorporated); ubiquitin (BD Transduction), FK1 (Biomol/Enzo Life Sciences), and FK2 (Biomol/Enzo Life Sciences). Western blots were visualized by enhanced chemiluminescence (GE Healthcare), and immunoreactive bands were digitally scanned and quantified with ImageJ software (NIH). Coimmunoreactivity was normalized to the level of immunoprecipitated PSD-95 and expressed as a percentage of control levels. Values are expressed as mean ± SEM and were statistically compared using Student’s t test.

Mass spectrometry. PSD-95 was immunoprecipitated from acute mouse forebrain slices treated with roscovitine as described above (Acute forebrain slices). Each eluted protein sample was reduced and alkylated, digested with either LysC/Trypsin or GluC/Trypsin, and phospho-enriched with an in-house developed TiO₂ enrichment strategy (Rinehart et al., 2009) to optimize for the observed >80% sequence coverage, which encompasses 29 of the 38 lysines in mouse PSD-95. Both flow-through and phospho-enriched fractions were injected onto a C18 RP Atlantis column attached to a nanoACQUITY UPLC system in line with a hybrid LTQ or Velos Orbitrap LC MS/MS instrument. Collected raw data from 13 experiments were processed by Distiller software (Matrix Science) and searched with the Mascot search engine. Ubiquitinated sites were identified by the addition of a Gly–Gly moiety on lysines and were manually validated.

Dissociated hippocampal cultures and immunocytochemistry. Dissociated hippocampal cultures were prepared from E17–E18 rat brains as described previously (Zhang et al., 2008). Hippocampal neurons were plated on coverslips coated with poly-D-lysine and laminin at a density of 6600/cm² and grown in Neurobasal medium supplemented with B27 (Biomol/Enzo Life Sciences), and FK2 (Biomol/Enzo Life Sciences). PSD-95 (Antibodies Incorporated); ubiquitin (BD Transduction), FK1 (Biomol/Enzo Life Sciences), and FK2 (Biomol/Enzo Life Sciences). Western blots were visualized by enhanced chemiluminescence (GE Healthcare), and immunoreactive bands were digitally scanned and quantified with ImageJ software (NIH). Coimmunoreactivity was normalized to the level of immunoprecipitated PSD-95 and expressed as a percentage of control levels. Values are expressed as mean ± SEM and were statistically compared using Student’s t test.

Results

Decreased Cdk5 activity increases PSD-95 ubiquitination
To assess whether Cdk5 regulates PSD-95 ubiquitination, we analyzed the levels of PSD-95 ubiquitination in p35 knock-out mice, which have reduced Cdk5 activity by 78% (Hallows et al., 2006). Immunoblotting of PSD-95 immunoprecipitated from brain revealed a more than fourfold increase in PSD-95 ubiquitination in p35 knock-out mice compared to wild-type littermates (431.3 ± 84.4% vs. 100 ± 18.5% for wild type; n = 3; p < 0.05; Fig. 1A), with a pattern of discrete bands similar to that obtained in p35 knock-out mice. Quantification revealed that PSD-95 ubiquitination in p35 knock-out mice was 431.3 ± 84.4% versus 100 ± 18.5% for wild type (n = 3; p < 0.05). The ubiquitin immunoreactivity was normalized to the level of immunoprecipitated PSD-95 and expressed as a percentage of wild-type control. B, Roscovitine treatment increases PSD-95 ubiquitination. Acute mouse forebrain slices were treated with the Cdk5 inhibitor roscovitine (10 μM, 45 min) or DMSO as the control. Immunoblots of PSD-95 immuno precipitated from lysates revealed increased ubiquitination of PSD-95 in roscovitine-treated (R) slices relative to control (D), with a pattern of discrete bands similar to that obtained in p35 knock-out mice. Quantification revealed that PSD-95 ubiquitination was 274.6 ± 71.6% with roscovitine treatment versus 100 ± 54.5% in untreated control (n = 4; p < 0.01). Ubiquitin immunoreactivity was normalized to the level of immunoreprecipitated PSD-95 and expressed as a percentage of DMSO control. C, PSD-95 is ubiquitinated on multiple lysines. PSD-95 immunoprecipitated from acute mouse forebrain slices treated with the Cdk5 inhibitor roscovitine (10 μM, 45 min) was subjected to LC/MS/MS analysis. Peptides obtained covered >80% of the PSD-95 primary amino acid sequence (DL64, mouse; Swiss-Prot database). A schematic view of PSD-95 domain structure with ubiquitinated lysines (K) is shown. Lysine residues ubiquitinated are K 10 in the N terminus, K 403 in the linker between the PDZ3 and SH3 domains, and K 544, K 672, and K 679 in the GK domain.

PSD-95 contains multiple protein–protein interaction motifs including an N-terminal domain, three PDZ domains, an SH3...
(Src homology 3) domain, and a GK (guanylate kinase) domain (Kim and Sheng, 2004; Montgomery et al., 2004). To identify the ubiquitinated lysines on PSD-95, we performed high-resolution tandem mass spectrometry analysis on PSD-95 immunoprecipitated from acute mouse forebrain slices treated with roscovitine. High molecular weight (MW) and long peptides generally pose difficulty in collision-induced dissociation-type fragmentation by most tandem mass spectrometers. Based on theoretically predicted digestion using various enzymes, we found that by including either GluC (Staphylococcus aureus protease V8) or LysC (endoproteinase from Lysobacter enzymogenes) with a trypsin digestion of PSD-95, we eliminated all the high MW peptides (peptides with MW > 3500) generated from just using trypsin. The combination of GluC or LysC with trypsin digestion resulted in > 80% primary protein sequence coverage of PSD-95 (DLG4, mouse; Swiss-Prot database), overlapping 29 of the 38 lysines, with Lys 152, Lys 157, Lys 162, Lys 166, Lys 211, Lys 255, Lys 503, Lys 505, and Lys 624, not represented. The presence of a Gly–Gly moiety on a lysine residue corresponds to the C terminus of the ubiquitin tag, which is present when trypsin (or a combination of GluC/trypsin enzymes) is used for enzymatic digestion before LC MS/MS analysis, and is indicative of ubiquitination. We identified five lysine residues of PSD-95 that were ubiquitinated after roscovitine treatment (Fig. 1C): Lys 10 in the N terminus, Lys 403 in the linker between PDZ3 and SH3 domains, and Lys 544, Lys 672, and Lys 679 in the GK domain. These results indicate that, under decreased Cdk5 activity, the N terminus as well as the PDZ3/SH3 linker region and the GK domain are ubiquitinated.

Mdm2 has been identified as the ubiquitin ligase for PSD-95 (Collede et al., 2003). Since the ubiquitination of PSD-95 is dependent on Mdm2, the increase in PSD-95 ubiquitination that we observed under reduced Cdk5 activity could reflect an increased interaction of PSD-95 with Mdm2. To investigate whether Cdk5 activity inversely correlates with the level of interaction of PSD-95 with Mdm2, we analyzed PSD-95 immunoprecipitated from brain lysates of p35 knock-out mice and wild-type controls. The number of costained puncta, as a percentage of total PSD-95 puncta, is expressed as a percentage of the number for DMSO controls. While polyubiquitination has been mainly associated with signaling functions (Hicke and Dunn, 2003; DiAntonio and Hicke, 2004; d’Azzo et al., 2005; Chen and Sun, 2009), we observed under reduced Cdk5 activity could reflect an increased interaction of PSD-95 with Mdm2, thus promoting PSD-95 ubiquitination. We identified five lysine residues of PSD-95 (Lys 10 in the N terminus, Lys 403 in the linker between PDZ3 and SH3 domains, and Lys 544, Lys 672, and Lys 679 in the GK domain). These results indicate that, under decreased Cdk5 activity, the N terminus as well as the PDZ3/SH3 linker region and the GK domain are ubiquitinated.

Decreased Cdk5 activity increases PSD-95 ubiquitination without a decrease in PSD-95 protein levels
Ubiquitination may occur by the addition of a single ubiquitin moiety to one or multiple lysine residues (monoubiquitination) or by addition of polymeric ubiquitin chains (polyubiquitination) (DiAntonio and Hicke, 2004; d’Azzo et al., 2005). While Mdm2 can catalyze both monoubiquitination and polyubiquitination (Li et al., 2003), the discrete ubiquitinated PSD-95 species that we observe and that were originally identified by Collede et al. (2003) suggest PSD-95 monoubiquitination on multiple sites. The FK1 and FK2 monoclonal antibodies are used to differentiate between monoubiquitination and polyubiquitination, since FK2 detects both monoubiquitinated and polyubiquitinated proteins, while FK1 recognizes only polyubiquitinated proteins (Fujimuro et al., 1994). Therefore, to assess whether the ubiquitination of PSD-95 reflects monoubiquitination or polyubiquitination, we tested PSD-95 from p35 knock-out mice for immunoblotting with FK1 and FK2 antibodies. Immuneblotting of PSD-95 immunoprecipitated from p35 knock-out brain revealed that PSD-95 ubiquitination is detected by FK2, not FK1. Polyubiquitinated species observed in the input lanes serve as a positive control for FK1 immunoreactivity (Fig. 3A). Similar results were obtained with PSD-95 immunoprecipitated from roscovitine-treated acute forebrain slices (Fig. 3B). The immunoreactivity of PSD-95 to FK2 but not to FK1 suggests monoubiquitination of PSD-95 on multiple lysines and is consistent with the LC MS/MS results.

While polyubiquitination has been mainly associated with targeting of proteins for degradation by the 26S proteasome, monoubiquitination has been implicated in nonproteosomal signaling functions (Hicke and Dunn, 2003; DiAntonio and Hicke, 2004; d’Azzo et al., 2005; Chen and Sun, 2009). To assess the relationship between PSD-95 ubiquitination and degradation, we analyzed the levels of PSD-95 in brain lysates of p35 knock-out and wild-type mice (Fig. 3C) and in roscovitine-treated and control acute forebrain slices (Fig. 3D). We observed no significant change in PSD-95 protein levels (normalized to actin) in p35 knock-out mice compared to wild-type littermates (120.7 ± 30.5% vs 100 ± 15.7% for wild type; n = 4; p > 0.5) or in roscovitine-treated slices compared to control (103.7 ± 18.7% vs 100 ± 15.8% for control; n = 3; p > 0.5). Thus, these results indicate that PSD-95 ubiquitination does not directly correlate with decreased PSD-95 protein levels, suggesting a nonproteolytic function for ubiquitinated PSD-95 at the synapse.
Since p35 knock-out mice have increased PSD-95 ubiquitination, we used these mutant mice to assess whether PSD-95 ubiquitination correlates with changes in PSD-95 interaction with AP-2 in vivo. We analyzed the interaction of PSD-95 with AP-2 in brain lysates of p35 knock-out and wild-type littermates by immunoblottting immunoprecipitated PSD-95 for the AP-2 subunit β-adaptin (Fig. 4A). The interaction of PSD-95 with β-adaptin was significantly increased in p35 knock-out mice (265 ± 55.8%) versus wild type (100 ± 16.4%; n = 4; p < 0.05). We also analyzed whether β-adaptin colocalizes with PSD-95 puncta in cultured hippocampal neurons treated with roscovitine (Fig. 4B). Immunocytochemistry analysis of these neurons revealed that roscovitine treatment promotes colocalization of β-adaptin with PSD-95 puncta compared to DMSO-treated control sister neurons (192.5 ± 19% vs 100 ± 15.6% for control; n = 5; p < 0.01). Thus, these data indicate that decreased Cdk5 activity, which promotes PSD-95 ubiquitination, also promotes the interaction of PSD-95 with β-adaptin. To further assess whether PSD-95 ubiquitination regulates the interaction with AP-2, we analyzed PSD-95 immunoprecipitated from brain lysates of Mdm2/p53 double knock-out mice, since Mdm2 knock-out mice die early in development (Jones et al., 1995), and control p53 knock-out mice (Fig. 4C). Immunoblot analysis of Mdm2/p53 double knock-out brain lysates revealed decreased interaction of PSD-95 with β-adaptin compared to control p33 knock-out mice (63.7 ± 8.8% vs 100 ± 10.8% for control; n = 5; p < 0.05). Together, these results indicate a correlation between the genetic deletion of Mdm2 and the decrease in PSD-95 interaction with β-adaptin and, conversely, between decreased Cdk5 activity and increased PSD-95 interaction with β-adaptin. Therefore, these results support a correlation between PSD-95 ubiquitination and interaction with β-adaptin, suggesting a function for ubiquitinated PSD-95 in the regulation of its interaction with the AP-2/clathrin endocytic complex.

PSD-95 ubiquitination is also induced by NMDA treatment (Colledge et al., 2003); thus, we investigated whether NMDA treatment regulates the interaction of PSD-95 with β-adaptin. Acute forebrain slices from adult wild-type mice were treated with NMDA (100 μM, 3 min), a treatment that induces AMPAR endocytosis (Bhattacharya et al., 2009), and analyzed at 5 and 10 min after NMDA washout. Immunoblot analysis of PSD-95 immunoprecipitated from the lysates revealed an increase in both PSD-95 ubiquitination and interaction with β-adaptin 10 min after NMDA washout (Fig. 4D). To further assess the correlation between PSD-95 ubiquitination and interaction with β-adaptin, we analyzed acute brain slices of adult Mdm2/p53 double knock-out mice and control p53 knock-out mice 5 and 10 min after NMDA (100 μM, 3 min) washout (Fig. 4E). Immunoblot analysis of PSD-95 immunoprecipitated from lysates of control p53 knock-out mice revealed an increase in PSD-95 interaction with β-adaptin at 5 min (209.0 ± 72.6%; n = 3) and 10 min (549.8 ± 168%; n = 3) after washout compared to the unstimulated control condition (100 ± 14.9%; n = 3). In contrast, the interaction of PSD-95 with β-adaptin was consistently lower in Mdm2/p53 double knock-out slices in unstimulated conditions (50.5 ± 13.8%; n = 3) at 5 min (45.6 ± 1.8%; n = 3) and 10 min (99.8 ± 43.7%; n = 3) after NMDA washout compared to unstimulated p53 knock-out control conditions. All the values obtained for the PSD-95/β-adaptin interaction in p53 and Mdm2/p53 double knock-outs were statistically significant (p < 0.005, ANOVA). These results indicate that the interaction of PSD-95 with β-adaptin is regulated by NMDARs and depends on Mdm2 expression. Thus, together these data support a direct correlation.

PSD-95 ubiquitination promotes the interaction with the clathrin endocytic adaptor complex AP-2

AMPAR endocytosis is mediated by the clathrin endocytic adaptor complex AP-2 (Carroll et al., 1999; Man et al., 2000). While the function of PSD-95 in AMPAR endocytosis is not clear, it has been shown that PSD-95 interacts with the AP-2 complex (Fernandez et al., 2009), and the AP-2 binding motif (YXXΦ) within the GK domain of PSD-95 (Y704HKV) is sufficient to mediate clathrin-dependent endocytosis of the transmembrane protein Tac (Craven and Bredd, 2000). Therefore, we hypothesize that PSD-95 ubiquitination functions by regulating the interaction of PSD-95 with the AP-2 complex.
between PSD-95 ubiquitination and interaction with AP-2, suggesting that PSD-95 ubiquitination may function in NMDAR-dependent AMPAR endocytosis by regulating the interaction with the clathrin endocytic adaptor complex AP-2.

**Discussion**

Cdk5 has been implicated in synaptic plasticity, but the molecular mechanisms are still not clear. PSD-95 ubiquitination by Mdm2 is stimulated by NMDAR activity and has been implicated in the regulation of NMDAR-induced internalization of AMPARs during synaptic plasticity. Here we show that PSD-95 ubiquitination is increased by genetic or pharmacological reduction of Cdk5 activity reflects ubiquitination on multiple lysines and does not correlate with decreased PSD-95 protein levels in vivo. We also show that PSD-95 ubiquitination correlates with increased interaction with the AP-2 complex both in p35 knock-out mice, which have reduced Cdk5 activity, and by direct stimulation of acute forebrain slices with NMDA. Together these results suggest a molecular mechanism by which Cdk5 impacts synaptic plasticity by regulating PSD-95 ubiquitination and its interaction with AP-2.

We provide evidence that reduced Cdk5 activity promotes the colocalization and interaction of Mdm2 with PSD-95 and the ubiquitination of PSD-95 in neurons. Mdm2 activity is regulated by numerous signaling pathways and is affected by changes in its stability and intracellular distribution (Mukhopadhyay and Riezman, 2007; Wade et al., 2010). Thus, reduced Cdk5 activity may promote PSD-95 ubiquitination by regulating the intracellular distribution of Mdm2 within neurons, possibly by increasing Mdm2 levels at the PSD. Mdm2 can catalyze both monoubiquitination and polyubiquitination of the tumor suppressor p53 (Li et al., 2003) and the pattern of discrete bands of ubiquitinated PSD-95 observed by Colledge et al., (2003), and in our experiments, suggests monoubiquitination on multiple lysines. Our study, using the differential immunoreactivity to the FK1 and FK2 antibodies, is consistent with PSD-95 monoubiquitination on multiple lysines. We have also identified, by high-resolution mass spectrometry, five ubiquitinated residues in PSD-95 from roscovitine-treated slices, although some regions of PSD-95 were not covered by our analysis, possibly due to ions not being ionized in the positive mode in the mass spectrometer, therefore making the peptides more observable in the negative mode (Toll et al., 2005). The identification of five ubiquitinated lysine residues in PSD-95 suggests that the three distinct bands of ubiquitinated PSD-95 observed in our experiments and by Colledge et al., (2003) may represent different combinations of ubiquitinated residues, with the high molecular weight band being consistent with three ubiquitinated residues. Interestingly, one of the lysines (Lys 10) is within the N-terminal domain of PSD-95, which has been implicated in homotypic interactions (Hsueh et al., 1997; Morabito et al., 2004; Xu et al., 2008). Lysine 10 is also adjacent to the PEST [proline (P), glutamic acid (E), serine (S), and threonine (T)] rich motif of PSD-95, which is required for NMDAR-induced AMPAR endocytosis (Colledge et al., 2003). Additional ubiquitinated lysines are in the linker between the PDZ2 and SH3 domains (Lys 403) and within the GK domain (Lys 544, Lys 672, and Lys 679). The
SH3 and GK domains are linked by a pair of antiparallel strands and form an integrated structural unit (McGee et al., 2001; Tavares et al., 2001). Lys 544, Lys 672, and Lys 679 are within α helix structures of the GK domain, suggesting that ubiquitination of these residues may change the conformation of the SH3/GK domain through the sterical presence of the ubiquitin moiety, making PSD-95 more accessible for protein interactions. In addition, the SH3 and GK domains are important for the localization of PSD-95 at the PSD, and hence for the effect of PSD-95 on AMPAR EPSCs (Xu et al., 2008). Thus, addition of ubiquitin moieties to these domains may regulate PSD-95 protein interactions, the organization of signaling molecules and cytoskeletal elements, and the strength of synaptic transmission.

In our study, PSD-95 ubiquitination does not correlate with its degradation both in p35 knock-out brain in vivo and in roscovitine-treated neurons, and is consistent with PSD-95 monoubiquitination. Previous studies have associated PSD-95 ubiquitination with its proteasomal degradation by showing that deletion of the PEST motif in PSD-95 or treatment with the proteasome inhibitor MG132 (C6, H8, N7, O8) protects PSD-95 from degradation (Colledge et al., 2003). Interestingly, the proteases calpain and caspase can catalyze PSD-95 degradation (Lu et al., 2000; Vinade et al., 2001; Gascón et al., 2008; Liu et al., 2010), and MG132 is also an inhibitor of calpains (Lee and Goldberg, 1998; Elliott et al., 2003). Furthermore, Lys 10 in PSD-95, which is ubiquitinated under reduced Cdk5 activity, is adjacent to the PEST motif, which has been implicated in proteolysis by caspases (Belizario et al., 2008) and calpains (Rechsteiner and Rogers, 1996; Shumway et al., 1999).

Our studies suggest a novel function for ubiquitinated PSD-95 at the synapse in the regulation of PSD-95 interaction with the clathrin endocytic adaptor complex AP-2. We observe a correlation between reduction of Cdk5 activity, increased PSD-95 ubiquitination, and increased PSD-95 interaction with β-adaptin, a component of AP-2/clathrin adaptor protein complex. We also observe the NMDAR-dependent increase in PSD-95 ubiquitination, first described by Colledge et al., (2003), accompanied by the increase in PSD-95 interaction with β-adaptin. The correlation between PSD-95 ubiquitination and increased interaction with AP-2 is further supported by our observation that, whereas in p35 knock-out mice NMDAR activity induces an increase in PSD-95 interaction with β-adaptin, this increase is greatly reduced in mice with a genetic deletion of Mdm2. Our results are consistent with previous studies indicating an interaction between PSD-95 and AP-2 (Fernandez et al., 2009) and a function for the motif within the GK domain of PSD-95 in mediating the clathrin-dependent endocytosis of the transmembrane protein Tac (Craven and Bredd, 2000). Together these observations suggest that ubiquitinated PSD-95 functions in recruiting the clathrin/AP-2 endocytic complex and possibly regulating the interaction with other postsynaptic proteins. Our data demonstrate that Cdk5 regulates the ubiquitination of PSD-95 and its interaction with AP-2. Given that ubiquitination of PSD-95 has been implicated in NMDAR-induced endocytosis of AMPARs, the recruitment of the clathrin/AP-2 endocytic complex by PSD-95 could provide a mechanism by which Cdk5 could modulate AMPAR internalization during synaptic plasticity.

References
Kalia LV, Pitcher GM, Kelley KA, Salter MW (2006) PSD-95 is a negative regulator of the tyrosine kinase Src in the NMDA receptor complex. EMBO J 25:4971–4982.
Bianchetta et al. • Cdk5 Regulates PSD-95 Ubiquitination


